Observational studyJournal of managed care & specialty pharmacy2026
Health care costs associated with disease progression of untreated chronic hepatitis C in the United States.
Observational study in Journal of managed care & specialty pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite effective direct-acting antiviral therapies, two-thirds of US patients with chronic hepatitis C remain untreated, leading to significant public health and economic challenges. However, data on the economic burden of untreated chronic hepatitis C in the direct-acting antiviral era remain limited.
objectiveTo estimate health care costs related to disease progression among untreated, newly diagnosed adults with chronic hepatitis C in the United States.
methodsWe conducted a retrospective observational study using US national commercial insurance data from January 2013 to December 2023. The cohort included adults aged 18 years or older with newly diagnosed, treatment-naive, and untreated chronic hepatitis C. Patients were categorized by liver disease stage-specific periods (chronic hepatitis C, compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, and liver transplantation), defined by the earliest recorded diagnosis of each stage and censored at progression. Liver disease-related costs, defined as costs with a primary diagnosis corresponding to these stages, were estimated using a 2-part model to account for excess zero costs. All-cause costs were estimated using generalized linear models with a γ distribution. Costs were calculated per person per month in 2023 US dollars.
resultsAmong 36,923 untreated patients with chronic hepatitis C, adjusted all-cause health care costs per patient per month increased substantially with disease progression: $4,483 (95% CI = $4,326-$4,640) for chronic hepatitis C, $6,240 ($5,570-$6,910) for compensated cirrhosis, $14,166 ($12,259-$16,073) for decompensated cirrhosis, $19,021 ($15,283-$22,758) for hepatocellular carcinoma, and $27,836 ($9,325-$46,348) at the liver transplant stage (
conclusionsThese findings highlight the critical importance of early treatment to reduce health care costs and improve clinical outcomes. Early screening and treatment can prevent progression to high-cost advanced liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.